Luminopia Funding Round

6/28/2023

Venture Equity

$16,000,000

Series A

The funding will be used to support the full commercial rollout later this year of the company's lead product, Luminopia, a software-based therapeutic for amblyopia, commonly known as "lazy eye," the leading cause of vision loss among children. Luminopia was approved by the U.S. Food and Drug Administration (FDA) through the De Novo pathway in October 2021 and is currently available for prescription-use only through eye care professionals. The company is currently being prescribed at top eye institutes and private practices across the country and is dispensed through a retail pharmacy.

Private & Independent

Healthcare Services

955 Massachusetts Ave 335
Cambridge, MA 02139
USA

Around 15 million Americans suffer from vision loss caused by deficiencies in the brain, instead of any structural issues with the eyes. Traditional therapeutic modalities are unable to properly target and treat these deficits, leaving a significant unmet need. By harnessing the latest in digital technology, we're creating an entirely new category of medicines to address these conditions. We develop software products that generate therapeutic visual stimuli and deliver them to the patient through a virtual reality headset, using the eyes to stimulate the brain. The success of our amblyopia therapeutic provides proof-of-concept for our broader platform.